FRMD3 Activators are a series of compounds that, through their influence on various signaling molecules and pathways, could enhance the functional activity of FRMD3, a protein involved in cytoskeletal organization and cell signaling. Forskolin, for instance, by increasing intracellular cAMP levels, could activate protein kinase A (PKA), which can phosphorylate proteins and possibly augment FRMD3's role in organizing the actin cytoskeleton. Similarly, Epidermal Growth Factor (EGF) activates its receptor, leading to a signaling cascade that may modulate the actin cytoskeleton, thereby potentially influencing FRMD3's functional activity. Phalloidin, by stabilizing F-actin, might enhance the interaction of FRMD3 with the cytoskeleton, while Lithium Chloride, through the inhibition of GSK-3β, could indirectly activate the Wnt pathway and stabilize cellular structures, potentially enhancing FRMD3's interaction with cytoskeletal components.
Calyculin A, by inhibiting phosphatases, could alter the phosphorylation state of proteins interacting with FRMD3, thereby affecting its signaling role. Jasplakinolide's stabilization of actin filaments might enhance FRMD3's cytoskeletal interactions. ML-7's inhibition of myosin light chain kinase (MLCK) may affect cytoskeletal dynamics, enhancing FRMD3's activity in these processes. Blebbistatin, a myosin II ATPase inhibitor, could alter cytoskeletal tension, potentially facilitating FRMD3's structural role. NSC 23766, a Rac1 inhibitor, might modify actin organization, leading to the enhanced activity of FRMD3 in related signaling processes. Lastly, Wiskostatin's inhibition of the N-WASP-Arp2/3 complex may influence actin polymerization, which could indirectly enhance the activity of FRMD3 in cytoskeletal dynamics. Together, these chemical compounds represent potential activators that, through their targeted effects on cellular signaling molecules and pathways, could facilitate the enhancement of FRMD3-mediated functions without the need for upregulating its expression or direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Elevates cAMP, which can activate PKA, leading to phosphorylation events that may enhance FRMD3's role in cytoskeletal organization and associated signaling. | ||||||
Phalloidin | 17466-45-4 | sc-202763 | 1 mg | $234.00 | 33 | |
Stabilizes F-actin, potentially increasing the stability of cellular structures where FRMD3 is involved, enhancing its interaction with the actin cytoskeleton. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3β indirectly leading to Wnt pathway activation, which could stabilize cellular structures and influence FRMD3's interactions with the cytoskeleton. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Inhibits protein phosphatases 1 and 2A, potentially altering the phosphorylation state of proteins that interact with FRMD3, affecting its signaling functions. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Stabilizes actin filaments, possibly enhancing FRMD3's interaction with the cytoskeleton and its signaling roles. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Inhibits myosin light chain kinase (MLCK), potentially affecting cytoskeletal dynamics and thus FRMD3's functional activity in cytoskeletal organization. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Inhibits myosin II ATPase activity, potentially affecting the cytoskeletal tension and enhancing FRMD3's role in cytoskeletal organization. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Inhibits Rac1, potentially modifying actin organization and leading to enhanced functional activity of FRMD3 in cell signaling related to cytoskeletal rearrangements. | ||||||
FLI-06 | 313967-18-9 | sc-497529 | 5 mg | $82.00 | ||
Inhibits the N-WASP-Arp2/3 complex, potentially affecting actin polymerization and thereby influencing FRMD3's activity in cytoskeletal dynamics. | ||||||